Arcutis reports topline phase II data on roflumilast topical foam for seborrheic dermatitis Sep. 30, 2020
Hoth reports research findings on ability of HT-003 to block acne pathogenic gene expression Sep. 28, 2020
Amytrx launches and puts its anti-inflammatory peptide into the clinic Sep. 18, 2020 By Lee Landenberger Amytrx Therapeutics Inc., of Nashville, Tenn., founded in 2014 but coming out of stealth now, is developing a therapeutic for treating multiple inflammatory, autoimmune and metabolic diseases. Read More
RSS
